All In Biotech

Drug Trial Radar · NCT00856986

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes. A 26 Week, Randomised, Open-label, Parallel-group, Multicentre, Multinational Trial With a 26 Week Extension

Last checked: Nov 20, 2026Latest source record: Mar 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 987 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

987

Actual

Start

Mar 2009

Primary completion

Apr 2010

Study completion Nov 2010

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Mar 6, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Europe and North America. The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus liraglutide and metformin in subjects with type 2 diabetes. Subjects will continue their own pre-trial metformin treatment during the trial.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • liraglutideDrug

    Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.

  • insulin detemirDrug

    Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm

  • metforminDrug

    Metformin tablets, at least 1500 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.Time frame: Week 0 (Randomisation), week 26

Locations

233 sites in 10 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Alexander City, Alabama

  • Novo Nordisk Investigational Site

    Birmingham, Alabama

  • Novo Nordisk Investigational Site

    Encino, California

  • Novo Nordisk Investigational Site

    Fullerton, California

  • Novo Nordisk Investigational Site

    Inglewood, California

  • Novo Nordisk Investigational Site

    La Jolla, California

  • Novo Nordisk Investigational Site

    Los Gatos, California

  • Novo Nordisk Investigational Site

    Montclair, California

  • Novo Nordisk Investigational Site

    Spring Valley, California

  • Novo Nordisk Investigational Site

    Tustin, California

  • Novo Nordisk Investigational Site

    Walnut Creek, California

  • Novo Nordisk Investigational Site

    Waterbury, Connecticut

  • Novo Nordisk Investigational Site

    Bradenton, Florida

  • Novo Nordisk Investigational Site

    Clearwater, Florida

  • Novo Nordisk Investigational Site

    Jupiter, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Atlanta, Georgia

  • Novo Nordisk Investigational Site

    Decatur, Georgia

  • Novo Nordisk Investigational Site

    Roswell, Georgia

  • Novo Nordisk Investigational Site

    Savannah, Georgia

  • Novo Nordisk Investigational Site

    Chicago, Illinois

  • Novo Nordisk Investigational Site

    Quincy, Illinois

  • Novo Nordisk Investigational Site

    Chicago Heights, Indiana

  • Novo Nordisk Investigational Site

    Louisville, Kentucky

  • Novo Nordisk Investigational Site

    Madisonville, Kentucky

  • Novo Nordisk Investigational Site

    Baltimore, Maryland

  • Novo Nordisk Investigational Site

    Hyattsville, Maryland

  • Novo Nordisk Investigational Site

    Rockville, Maryland

  • Novo Nordisk Investigational Site

    Methuen, Massachusetts

  • Novo Nordisk Investigational Site

    St Louis, Missouri

  • Novo Nordisk Investigational Site

    New Hyde Park, New York

  • Novo Nordisk Investigational Site

    Northport, New York

  • Novo Nordisk Investigational Site

    Syracuse, New York

  • Novo Nordisk Investigational Site

    The Bronx, New York

  • Novo Nordisk Investigational Site

    Charlotte, North Carolina

  • Novo Nordisk Investigational Site

    Durham, North Carolina

  • Novo Nordisk Investigational Site

    Cincinnati, Ohio

  • Novo Nordisk Investigational Site

    Cincinnati, Ohio

Showing 40 of 233 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.